PDI, TMAC form a strategic alliance

Share this article:
Contract sales firm PDI and The Medical Affairs Company (TMAC) signed an agreement aligning their respective services with the goal of providing clients with a more complete set of field-based commercialization solutions.

Saddle River, NJ-based PDI is a provider of sales and marketing support to US pharmaceutical companies, and TMAC, based in Keenesaw, GA, provides customized medical science liaison (MSL) and medical affairs services.
Under the exclusive agreement, PDI and TMAC will integrate their service offerings to benefit client brands, participate in joint client presentations and exchange new business leads.

By operating under this agreement, both PDI and TMAC are better able to meet a wider variety of client demands for best-in-class field resources, while preserving the important separation of pharma sales and medical departments.

Nancy Lurker, CEO, PDI, said that MSL plays an increasingly crucial role in pharmaceuticals today—that of providing high-level scientific information to key opinion leaders and other medical doctors on a peer-to-peer basis. She added that the company is very pleased to partner with TMAC through this strategic alliance.

Lurker noted that agreement will increase “PDI's ability to provide maximum value to our clients and fills a critical need for a higher science personal engagement with physicians.”

TMAC CEO Evan Demestihas, MD, said the agreement will give each company even greater leverage to build their business in the industry. Demestihas noted that with the partnership, each company gains a more complete suite of field services, placing them in a better position to seize growth opportunities.

PDI was one of the first contract services organizations to provide sales and marketing support to established and emerging US-based biopharmaceutical companies.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?